Kolexia
Peyraud Florent Oncologie médicale
Peyraud Florent
Oncologie médicale
Institut Bergonié
Bordeaux, France
217 Activités
307 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Sarcomes Tumeurs du poumon Carcinome pulmonaire non à petites cellules Carcinome pulmonaire à petites cellules Carcinomes Structures lymphoïdes tertiaires Tumeurs du rein Carcinome épidermoïde Nausée

Collaborateurs

Voir plus
Italiano Antoine
Italiano Antoine
Institut Bergonié, Bordeaux, France
Cousin Sophie
Cousin Sophie
Institut Bergonié, Bordeaux, France
Gross-Goupil Marine
Gross-Goupil Marine
Hôpital Saint-André, Bordeaux, France
Vienne Agathe
Vienne Agathe
Hôpital Saint Pierre, Saint-Pierre, France

Industries

Voir plus
A+A
4 collaboration(s)
Dernière en 2021
Pharma Mar
1 collaboration(s)
Dernière en 2023
{{person.topindus3.name}}
{{person.topindus3.tot}} collaboration(s)
Dernière en {{person.topindus3.last}}
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
Reshaping the tumor microenvironment of cold soft-tissue sarcomas with oncolytic viral therapy: a phase 2 trial of intratumoral JX-594 combined with avelumab and low-dose cyclophosphamide.
Molecular cancer   20 février 2024
Impact of metronomic trabectedin combined with low-dose cyclophosphamide on sarcoma microenvironment and correlation with clinical outcome: results from the TARMIC study.
Molecular cancer   19 février 2024
MEDISARC-SBRT: Phase I Study Evaluating the Safety and Efficacy of MEDI5752 in Combination With Stereotactic Radiotherapy in Patients With Metastatic Sarcoma
Essai Clinique (Institut Universitaire du Cancer Toulouse Oncopole)   12 janvier 2024
AMPHISARC: A Multicenter, Phase I/II Study Evaluating the Clinical Impact of HDM201 + Pazopanib in Patients With P53 Wild-type Advanced/ Metastatic Soft Tissue Sarcomas (AMPHISARC)
Essai Clinique (Centre Léon-Bérard)   06 décembre 2023
TROP2 is associated with primary resistance to immune checkpoint inhibition in patients with advanced non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research   01 décembre 2023
Upregulation of Indoleamine 2,3-dioxygenase 1 in tumor cells and tertiary lymphoid structures is a hallmark of inflamed non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research   26 septembre 2023
Abstract 2108: High prevalence of immune exclusion in cancer as determined by pathologist assessment and image analysis
Proceedings: AACR Annual Meeting 2023   01 avril 2023
Abstract 4341: Indoleamine 2,3-dioxygenase 1 is highly expressed in tertiary lymphoid structures and associated with improved outcome in patients with advanced non-small cell lung cancer treated with anti-PD1/PDL1 inhibitors
Proceedings: AACR Annual Meeting 2023   01 avril 2023
Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study.
Annals of oncology : official journal of the European Society for Medical Oncology   25 janvier 2023
Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM).
Annals of oncology : official journal of the European Society for Medical Oncology   17 septembre 2022